Yap Expression Is Closely Related to Tumor Angiogenesis and Poor Prognosis in Hepatoblastoma

References

• De Ioris M, Brugieres L, Zimmermann A, Keeling J, Brock P, Maibach R, Pritchard J, Shafford L, Zsiros J, Czaudzerna P, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. Eur J Cancer. 2008;44(4):545–50. doi:10.1016/j.ejca.2007.11.022.
   PubMed Web of Science ®Google Scholar
• D’Antiga L, Vallortigara F, Cillo U, Talenti E, Rugge M, Zancan L, Dall’Igna P, De Salvo G, Perilongo G. Features predicting unresectability in hepatoblastoma. Cancer. 2007;110(5):1050–8. doi:10.1002/cncr.22876.
   PubMed Web of Science ®Google Scholar
• Dong Q, Xu W, Jiang B, Lu Y, Hao X, Zhang H, Jiang Z, Lu H, Yang C, Cheng Y, et al. Clinical applications of computerized tomography 3-D reconstruction imaging for diagnosis and surgery in children with large liver tumors or tumors at the hepatic hilum. Pediatr Surg Int. 2007;23(11):1045–50. doi:10.1007/s00383-007-1910-1.
   PubMed Web of Science ®Google Scholar
• Czauderna P, Otte JB, Roebuck DJ, Schweinitz DV, Plaschkes J. Surgical treatment of hepatoblastoma in children. Pediatr Radiol. 2006;36(3):187–91. doi:10.1007/s00247-005-0067-0.
   PubMed Web of Science ®Google Scholar
• Meyers RL, Rowland JR, Krailo M, Chen Z, Katzenstein HM, Malogolowkin MH. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2009;53(6):1016–22. doi:10.1002/pbc.22088.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Li T, Zheng S, Wang H. The Hippo pathway as a drug target in gastric cancer. Cancer Lett. 2018;420:14–25. doi:10.1016/j.canlet.2018.01.062.
   PubMed Web of Science ®Google Scholar
• Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15(2):73–9. doi:10.1038/nrc3876.
   PubMed Web of Science ®Google Scholar
• Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;29(6):783–803. doi:10.1016/j.ccell.2016.05.005.
   PubMed Web of Science ®Google Scholar
• Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013;144(7):1530–42. doi:10.1053/j.gastro.2013.02.009.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhou D. Role of the transcriptional coactivators YAP/TAZ in liver cancer. Curr Opin Cell Biol. 2019;61:64–71. doi:10.1016/j.ceb.2019.07.006.
   PubMed Web of Science ®Google Scholar
• Tufail R, Jorda M, Wei Z, Reis I, Nawaz Z. Treatment. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat. 2012;131(3):743–50. doi:10.1007/s10549-011-1435-0.
   PubMed Web of Science ®Google Scholar
• Ling HH, Kuo CC, Lin BX, Huang YH, Lin CW. Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer. Exp Cell Res. 2017;350(1):218–25. doi:10.1016/j.yexcr.2016.11.024.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wei Q, Yang Y, Qin H, Li X, Cai S, Ma Y. Loss of Yes-associated protein represents an aggressive subtype of colorectal cancer. J Cancer. 2019;10(3):689–96. doi:10.7150/jca.28333.
   PubMed Web of Science ®Google Scholar
• Cho SY, Kim K, Park MS, Jang MY, Choi YH, Han S, Shin HM, Chung C, Han HY, Yang JB, et al. Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma. Oncol Rep. 2017;37(5):2620–32. doi:10.3892/or.2017.5517.
   PubMed Web of Science ®Google Scholar
• Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, et al. The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res. 2015;21(11):2580–90. doi:10.1158/1078-0432.CCR-14-2191.
   PubMed Web of Science ®Google Scholar
• Jin X, Zhao W, Zhou P, Niu T. YAP knockdown inhibits proliferation and induces apoptosis of human prostate cancer DU145 cells. Mol Med Rep. 2018;17(3):3783–8.
   PubMed Web of Science ®Google Scholar
• Yoo W, Lee J, Jun E, Noh KH, Lee S, Jung D, Jung KH, Kim JS, Park YY, Kim SC, et al. The YAP1–NMU axis is associated with pancreatic cancer progression and poor outcome: identification of a novel diagnostic biomarker and therapeutic target. Cancers (Basel). 2019;11:1477. doi:10.3390/cancers11101477.
   Web of Science ®Google Scholar
• Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, et al. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res. 2011;17(8):2130–9. 15. doi:10.1158/1078-0432.CCR-10-2467.
   PubMed Web of Science ®Google Scholar
• Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, Ranganathan S, Apte U. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int. 2012;32(1):38–47. doi:10.1111/j.1478-3231.2011.02646.x.
   PubMed Web of Science ®Google Scholar
• Tomlinson GE, Kappler R. Genetics and epigenetics of hepatoblastoma. Pediatr Blood Cancer. 2012;59(5):785–92. Novdoi:10.1002/pbc.24213.
   PubMed Web of Science ®Google Scholar
• Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015; 47(3):250–6. doi:10.1038/ng.3218.
   PubMed Web of Science ®Google Scholar
• Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, et al. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158(1):157–70. doi:10.1016/j.cell.2014.06.013.
   PubMed Web of Science ®Google Scholar
• Li C, Wang S, Xing Z, Lin A, Liang K, Song J, Hu Q, Yao J, Chen Z, Park PK, et al. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017;19(2):106–19. doi:10.1038/ncb3464.
   PubMed Web of Science ®Google Scholar
• Dai XY, Zhuang LH, Wang DD, Zhou TY, Chang LL, Gai RH, Zhu DF, Yang B, Zhu H, He QJ. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells. Oncotarget. 2016;7(6):6933–47. doi:10.18632/oncotarget.6903.
   PubMedGoogle Scholar
• Wang Z, Liu P, Zhou X, Wang T, Feng X, Sun YP, Xiong Y, Yuan HX, Guan KL. Endothelin promotes colorectal tumorigenesis by activating YAP/TAZ. Cancer Res. 2017;77(9):2413–23. doi:10.1158/0008-5472.CAN-16-3229.
   PubMed Web of Science ®Google Scholar
• Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61(5):1088–96. doi:10.1016/j.jhep.2014.06.033.
   PubMed Web of Science ®Google Scholar
• Yimlamai D, Fowl BH, Camargo FD. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol. 2015;63(6):1491–501. doi:10.1016/j.jhep.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, Jiang L, Fan B, Terracciano L, Armeanu-Ebinger S, et al. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014;147(3):690–701. Sepdoi:10.1053/j.gastro.2014.05.004.
   PubMed Web of Science ®Google Scholar
• Min Q, Molina L, Li J, Adebayo Michael AO, Russell JO, Preziosi ME, Singh S, Poddar M, Matz-Soja M, Ranganathan S, et al. β-Catenin and Yes-associated protein 1 cooperate in hepatoblastoma pathogenesis. Am J Pathol. 2019;189(5):1091–104. doi:10.1016/j.ajpath.2019.02.002.
   PubMed Web of Science ®Google Scholar
• Wang H, Lu J, Mandel JA, Zhang W, Schwalbe M, Gorka J, Liu Y, Marburger B, Wang J, Ranganathan S, et al. Patient-derived mutant forms of NFE2L2/NRF2 drive aggressive murine hepatoblastomas. Cell Mol Gastroenterol Hepatol. 2021;12(1):199–228. doi:10.1016/j.jcmgh.2021.02.004.
   PubMed Web of Science ®Google Scholar
• Koch A, Denkhaus D, Albrecht S, Leuschner I, Schweinitz Pietsch vDT. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 1999;59(2):269–73.
   PubMed Web of Science ®Google Scholar
• Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, Goga A, Balakrishnan A, Semeraro M, Gresh L, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 2008;14(6):471–84. doi:10.1016/j.ccr.2008.11.002.
   PubMed Web of Science ®Google Scholar
• López-Terrada D, Alaggio R, de Dávila MT, Czauderna P, Hiyama E, Katzenstein H, Leuschner I, Malogolowkin M, Meyers R, Ranganathan S, et al. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol. 2014;27(3):472–91. doi:10.1038/modpathol.2013.80.
   PubMed Web of Science ®Google Scholar
• Adesina AM, Lopez-Terrada D, Wong KK, Gunaratne P, Nguyen Y, Pulliam J, Margolin J, Finegold MJ. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol. 2009;40(6):843–53. doi:10.1016/j.humpath.2008.10.022.
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401–10. doi:10.1038/nrc1093.
   PubMed Web of Science ®Google Scholar
• Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol. 2011;12(9):551–64. doi:10.1038/nrm3176.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Carducci MA. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Cancer J. 2013;19(1):99–106. doi:10.1097/PPO.0b013e31827e0b86.
   PubMed Web of Science ®Google Scholar
• Dong R, Liu GB, Liu BH, Chen G, Li K, Zheng S, Dong KR. Targeting long non-coding RNA-TUG1 inhibits tumor growth and angiogenesis in hepatoblastoma. Cell Death Dis. 2016;7(6):e2278. doi:10.1038/cddis.2016.143.
   PubMedGoogle Scholar
• Wang X, Freire Valls A, Schermann G, Shen Y, Moya IM, Castro L, Urban S, Solecki GM, Winkler F, Riedemann L, et al. YAP/TAZ orchestrate VEGF signaling during developmental angiogenesis. Dev Cell. 2017;42(5):462–78.e7. doi:10.1016/j.devcel.2017.08.002.
   PubMed Web of Science ®Google Scholar
• Chen Q, Fan K, Chen X, Xie X, Huang L, Song G, Qi W. Ezrin regulates synovial angiogenesis in rheumatoid arthritis through YAP and Akt signalling. J Cell Mol Med. 2021;25(19):9378–89. doi:10.1111/jcmm.16877. Epub 2021 Aug 29.
   PubMed Web of Science ®Google Scholar